192 related articles for article (PubMed ID: 34506688)
21. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Ogata M; Sugio Y; Fukuda T; Uchida N; Ikegame K; Matsuoka KI; Shiratori S; Kondo T; Miyamoto T; Eto T; Ichinohe T; Kanda Y; Atsuta Y; Suzuki R;
Hematol Oncol; 2020 Apr; 38(2):146-152. PubMed ID: 31953867
[TBL] [Abstract][Full Text] [Related]
22. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Luo L; Zhang L; Cai B; Li H; Huang W; Jing Y; Zhu H; Zhao Y; Bo J; Wang Q; Han X; Yu L; Gao C
Ann Transplant; 2014 Jan; 19():6-12. PubMed ID: 24399278
[TBL] [Abstract][Full Text] [Related]
23. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
[TBL] [Abstract][Full Text] [Related]
25. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk.
Dharnidharka VR; Tejani AH; Ho PL; Harmon WE
Am J Transplant; 2002 Nov; 2(10):993-8. PubMed ID: 12482154
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
Jiménez S
Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
[TBL] [Abstract][Full Text] [Related]
27. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
28. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients.
Dos Santos Q; Wareham NE; Mocroft A; Rasmussen A; Gustafsson F; Perch M; Sørensen SS; Manuel O; Müller NJ; Lundgren J; Reekie J
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805050
[TBL] [Abstract][Full Text] [Related]
30. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
31. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study.
Francis A; Johnson DW; Teixeira-Pinto A; Craig JC; Wong G
Nephrol Dial Transplant; 2018 May; 33(5):881-889. PubMed ID: 29342279
[TBL] [Abstract][Full Text] [Related]
32. Posttransplantation lymphoproliferative disorder in children: manifestations in hematopoietic cell recipients in comparison with liver recipients.
Jeon TY; Kim JH; Eo H; Yoo SY; Yoo KH; Lee SK; Lim GY; Cheon JE
Radiology; 2010 Nov; 257(2):490-7. PubMed ID: 20829531
[TBL] [Abstract][Full Text] [Related]
33. Post-transplant lymphoproliferative disorder: no relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients.
Longmore DK; Conwell LS; Burke JR; McDonald SP; McTaggart SJ
Pediatr Transplant; 2013 Dec; 17(8):731-6. PubMed ID: 24164826
[TBL] [Abstract][Full Text] [Related]
34. Post-transplant lymphoproliferative disorder after pancreas transplantation: a United Network for Organ Sharing database analysis.
Jackson K; Ruppert K; Shapiro R
Clin Transplant; 2013; 27(6):888-94. PubMed ID: 24118329
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
[TBL] [Abstract][Full Text] [Related]
36. Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
Marinho-Dias J; Lobo J; Henrique R; Baldaque I; Pinho-Vaz C; Regadas L; Branca R; Campilho F; Campos A; Medeiros R; Sousa H
Mol Med Rep; 2018 Nov; 18(5):4650-4656. PubMed ID: 30221663
[TBL] [Abstract][Full Text] [Related]
37. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
38. Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies.
Ciurea SO; Kongtim P; Hasan O; Ramos Perez JM; Torres J; Rondon G; Champlin RE
Clin Cancer Res; 2020 May; 26(10):2404-2410. PubMed ID: 32019857
[TBL] [Abstract][Full Text] [Related]
39. Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder.
Major A; Kamdar M
Curr Treat Options Oncol; 2018 May; 19(7):33. PubMed ID: 29797086
[TBL] [Abstract][Full Text] [Related]
40. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
